|

Bulevirtide 2 mg and Brelovitug - 300 mg Clinical Trials

1 actively recruiting trial

Also known as: Hepcludex

Pipeline

Phase 3: 1

Top Sponsors

  • Mirum Pharmaceuticals, Inc.1

Indications

  • Liver Disease1
  • Chronic Hepatitis D Infection1

Other1 trial

A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.